Cogent Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Cogent Biosciences, Inc. (COGT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 929.23 thousand shares for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-28.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2019-03-28
- Cogent Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2018-12-31 was 55.70K shares.
- Cogent Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2018-09-30 was 43.98K shares.
- Cogent Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2018-06-30 was 52.48K shares.
- Cogent Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2018-03-31 was 777.07K shares.
- Cogent Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2018 was 929.23K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2018-12-31 | 55.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | 99.69K shares derived: sum of 2 quarters · filed 2019-03-28 | 152.16K shares derived: sum of 3 quarters · filed 2019-03-28 | 929.23K shares 10-K · filed 2019-03-28 |
| 2018-09-30 | 43.98K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | 96.46K shares derived: sum of 2 quarters · filed 2018-11-13 | 873.53K shares 10-Q · filed 2018-11-13 | |
| 2018-06-30 | 52.48K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | 829.55K shares 10-Q · filed 2018-08-13 | ||
| 2018-03-31 | 777.07K shares 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |